Related Experiment Video

Updated: Jun 5, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

New developments in treatment of ovarian carcinoma: focus on trabectedin

Philippe A Cassier1, Aude Duret, Olivier Trédan

  • 1Département de médecine.

Cancer Management and Research
|December 29, 2010
PubMed

Insights

Trabectedin, a marine compound, shows promise in treating soft tissue sarcoma, ovarian, and breast cancers. While effective in combination therapies, it carries risks of hematologic and hepatic toxicities.

Area of Science:

  • Marine pharmacology
  • Molecular oncology
  • DNA repair mechanisms

Background:

  • Trabectedin is a marine-derived antineoplastic agent.
  • It targets the DNA minor groove and DNA repair proteins.
  • Promising single-agent activity observed in soft tissue sarcoma, ovarian, and breast cancers.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of trabectedin in cancer treatment.
  • To assess combination therapies involving trabectedin.
  • To explore predictive factors and novel combinations for trabectedin therapy.

Main Methods:

  • Review of trabectedin's mechanism of action and clinical activity.
  • Analysis of toxicity profiles, including hematologic and hepatic effects.
  • Examination of Phase III trial data comparing trabectedin combinations.

Main Results:

  • Trabectedin demonstrates single-agent activity in pretreated patients.
  • Combination with pegylated liposomal doxorubicin (PLD) improved progression-free survival in ovarian cancer.
  • Significant toxicities include neutropenia, thrombocytopenia, and elevated liver enzymes.

Conclusions:

  • Trabectedin is a feasible option for combination chemotherapy.
  • Improved progression-free survival was noted with trabectedin and PLD combination therapy.
  • Future research priorities include identifying predictive biomarkers and developing new drug combinations.
Keywords:
DNA repairchemotherapycombinationdrug developmentovarian cancer

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...